Drug Approvals Might Skip 2nd Trial, Rely More On Clinical Pharmacology
Executive Summary
FDA looks to expand 1998 guidance with more scenarios where clinical pharmacology data may serve as confirmatory evidence for drug approval on the basis of a single adequate, well-controlled study.